Please check your internet connection and try again.
# Sompraz HP
## Overview
Sompraz HP is a combination product containing pantoprazole, amoxicillin, and clarithromycin, used for the eradication of *Helicobacter pylori* infection.
## Primary Indications
Eradication of *Helicobacter pylori* in patients with peptic ulcer disease.
## Adult Dosing
* **One (1) triple-pak administered orally twice daily for 7 days.** Each triple-pak typically contains:
* Pantoprazole 40 mg
* Amoxicillin 500 mg
* Clarithromycin 500 mg
## Pediatric Dosing
* Specific pediatric dosing is not established for Sompraz HP.
## Dose Adjustments
* **Renal Impairment:**
* Pantoprazole: Dose adjustment is generally not required for mild to moderate renal impairment. Use with caution in severe renal impairment.
* Amoxicillin: Dose adjustment is necessary for severe renal impairment (CrCl < 30 mL/min). Consult specific guidelines for dose reduction.
* Clarithromycin: Dose adjustment is necessary for significant renal impairment (CrCl < 30 mL/min). The recommended dose is 250 mg twice daily.
* **Hepatic Impairment:**
* Pantoprazole: Use with caution in severe hepatic impairment; a maximum daily dose of 20 mg is recommended.
* Amoxicillin: No dose adjustment is typically required.
* Clarithromycin: Use with caution in hepatic impairment, especially if also accompanied by renal impairment.
## Contraindications
* Hypersensitivity to pantoprazole, amoxicillin, clarithromycin, or any component of the formulation.
* History of cholestatic jaundice/hepatic dysfunction associated with prior clarithromycin use.
* Concomitant use with rifampin, rifabutin, or other potent CYP3A4 inducers (due to clarithromycin).
* Patients with known or suspected ventricular dysfunction (e.g., severe heart failure), QT prolongation, electrolyte disturbances, or concurrent use of other QT-prolonging drugs (due to clarithromycin).
* Severe renal impairment with concomitant administration of amoxicillin and clarithromycin (potential for accumulation).
## Adverse Effects
* **Common:** Diarrhea, nausea, abdominal pain, taste perversion, headache, rash, fungal infections.
* **Serious:** *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis), Stevens-Johnson syndrome, toxic epidermal necrolysis, *H. pylori* resistance, QT prolongation, torsades de pointes, hepatotoxicity.
## Key Drug Interactions
* **Clarithromycin:** Potent CYP3A4 inhibitor. Increases concentrations of drugs metabolized by CYP3A4 (e.g., statins, warfarin, carbamazepine, cyclosporine, tacrolimus, certain benzodiazepines, colchicine). Avoid concomitant use with colchicine; if unavoidable, reduce colchicine dose and monitor.
* **Pantoprazole:** May decrease absorption of drugs requiring acidic gastric pH (e.g., ketoconazole, itraconazole, certain HIV protease inhibitors). May interact with methotrexate.
* **Amoxicillin:** May decrease the efficacy of oral contraceptives.
## Monitoring
* Monitor for signs and symptoms of hypersensitivity reactions.
* Monitor for diarrhea and assess for *C. difficile* infection.
* Monitor liver function tests, particularly with prolonged use or in patients with hepatic impairment.
* Assess for *H. pylori* eradication post-treatment via stool antigen test or urea breath test.
## Clinical Pearls
* Administer the entire contents of each triple-pak as directed.
* Take 30 minutes before a meal.
* Patients with penicillin allergy should not receive amoxicillin.
* Ensure adequate hydration.
* Resistance to clarithromycin is a significant concern and can impact eradication rates.
***
**Disclaimer:** This information is intended for healthcare professionals and does not replace comprehensive drug information resources. Always consult the official prescribing information and relevant clinical guidelines for the most current and complete data before making any treatment decisions. Dosing and recommendations may vary based on individual patient factors and local protocols.
